viewBlueJay Mining PLC

BlueJay Mining says Dundas PFS to be next year as it incorporates engineering upgrades

The PFS will include a number of engineering optimisations currently being worked on

Ilmenite is a source of titanium

Bluejay Mining PLC (LON:JAY)  expects to publish the pre-feasibility study for its Dundas ilmenite project in Greenland in the first quarter of next year.

That is later than it originally anticipated but the PFS will include a number of engineering optimisations currently being worked on. Parts of the study will be released as they are completed but the full report will be in 2019, said the junior.

Bluejay has the highest grade ilmenite project anywhere in the world, and has secured big-name backers to help put it into production

In April, the resource estimate at Dundas was increased by 400% to 96mln tonnes at 6.9% ilmenite.

Today, Bluejay added offtake discussions are ongoing over the whole initial annual ilmenite production from Dundas.

An environmental and social impact assessment (ESIA) is due to be completed by the end of the year.

Mike Hutchinson, the chairman, said: "Although we are disappointed with the delays, it is important to note that these project optimisations will expand what is already an economic development into a significantly more robust long-term operation.”

Losses for the six months were £868,000 (£785,00).

Quick facts: BlueJay Mining PLC

Price: 8.65 GBX

Market: AIM
Market Cap: £80.44 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BlueJay Mining PLC named herein, including the promotion by the Company of BlueJay Mining PLC in any Content on the Site, the Company receives...



Investor Update: Allergy Therapeutics receives multi-million-dollar settlement

Top stories from the Proactive Investors UK newsroom. Allergy Therapeutics (LON:AGY) has accepted US$7.6mln in settlement of a dispute over the procedures used for a US grass pollen vaccine trial. Allergy blamed the inconclusive trial results on the way the study was carried...

on 27/6/19

2 min read